Pass on the Pink Pill

Addyi Health Fact Sheet

By NWHN Staff | Jul 30, 2018 | Comments Off on Addyi Health Fact Sheet

Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.

Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

By Shaniqua Seth | Aug 18, 2016 | Comments Off on Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

FOR IMMEDIATE RELEASE
Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225

Addyi 1 Year Later: What’s the Score?

By NWHN Staff | Aug 18, 2016 | Comments Off on Addyi 1 Year Later: What’s the Score?

Click image to download PDF of the report card. Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects…

Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New Campaign

By NWHN Staff | Nov 18, 2015 | Comments Off on Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New Campaign

FOR IMMEDIATE RELEASE

Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043

New Campaign Warns Women of Harm from Drug FDA Approved in August

By Cindy Pearson | Nov 17, 2015 | Comments Off on New Campaign Warns Women of Harm from Drug FDA Approved in August

FOR IMMEDIATE RELEASE
To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994

Warning of Marginal Benefits and Serious Side Effects as Drug Sales Begin

By Cindy Pearson | Nov 12, 2015 | Comments Off on Warning of Marginal Benefits and Serious Side Effects as Drug Sales Begin

FOR IMMEDIATE RELEASE

To schedule an interview with Cindy Pearson and Susan Wood, contact Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994